7.59 USD
+0.35 (+4.83%)
7.591 USD
+0 (+0.01%)
MEDS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. The financial health of MEDS is average, but there are quite some concerns on its profitability. MEDS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MEDS had negative earnings in the past year.
In the past year MEDS has reported a negative cash flow from operations.
MEDS had negative earnings in each of the past 5 years.
MEDS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
MEDS has a better Return On Assets (28.09%) than 97.44% of its industry peers.
MEDS's Return On Equity of 35.39% is amongst the best of the industry. MEDS outperforms 97.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.09% | ||
| ROE | 35.39% | ||
| ROIC | N/A |
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MEDS has a Profit Margin of 94.17%. This is amongst the best in the industry. MEDS outperforms 97.44% of its industry peers.
MEDS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 94.17% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MEDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MEDS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MEDS has more shares outstanding
MEDS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.40, we must say that MEDS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.40, MEDS is not doing good in the industry: 61.54% of the companies in the same industry are doing better.
MEDS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.4 |
ROIC/WACCN/A
WACC11.3%
2.3 Liquidity
A Current Ratio of 4.18 indicates that MEDS has no problem at all paying its short term obligations.
MEDS has a better Current ratio (4.18) than 74.36% of its industry peers.
MEDS has a Quick Ratio of 4.18. This indicates that MEDS is financially healthy and has no problem in meeting its short term obligations.
MEDS's Quick ratio of 4.18 is fine compared to the rest of the industry. MEDS outperforms 79.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 |
3. Growth
3.1 Past
MEDS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.73%, which is quite impressive.
The Revenue for MEDS has decreased by -53.03% in the past year. This is quite bad
Measured over the past years, MEDS shows a quite strong growth in Revenue. The Revenue has been growing by 16.65% on average per year.
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MEDS. In the last year negative earnings were reported.
Also next year MEDS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 125.16%, MEDS is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 4.65, MEDS pays a better dividend. On top of this MEDS pays more dividend than 100.00% of the companies listed in the same industry.
MEDS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 125.16% |
5.2 History
MEDS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
7.59
+0.35 (+4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners0.02%
Inst Owner Change0%
Ins Owners309.26%
Ins Owner Change0%
Market Cap11.08M
Revenue(TTM)4.43M
Net Income(TTM)4.17M
Analysts82.86
Price Target6.89 (-9.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 125.16% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.59%
Min Revenue beat(2)-100%
Max Revenue beat(2)-99.18%
Revenue beat(4)0
Avg Revenue beat(4)-53.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-1.65%
Revenue beat(8)1
Avg Revenue beat(8)-31.56%
Revenue beat(12)5
Avg Revenue beat(12)-13.38%
Revenue beat(16)7
Avg Revenue beat(16)-4.94%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.94 | ||
| P/tB | 0.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-6.71
FCFYN/A
OCF(TTM)-5.1
OCFYN/A
SpS3.03
BVpS8.07
TBVpS8.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.09% | ||
| ROE | 35.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 94.17% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 | ||
| Altman-Z | -2.4 |
F-Score4
WACC11.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-909.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.13%
OCF growth 3YN/A
OCF growth 5YN/A
TRXADE HEALTH INC / MEDS FAQ
Can you provide the ChartMill fundamental rating for TRXADE HEALTH INC?
ChartMill assigns a fundamental rating of 3 / 10 to MEDS.
What is the valuation status of TRXADE HEALTH INC (MEDS) stock?
ChartMill assigns a valuation rating of 0 / 10 to TRXADE HEALTH INC (MEDS). This can be considered as Overvalued.
How profitable is TRXADE HEALTH INC (MEDS) stock?
TRXADE HEALTH INC (MEDS) has a profitability rating of 2 / 10.
How financially healthy is TRXADE HEALTH INC?
The financial health rating of TRXADE HEALTH INC (MEDS) is 6 / 10.
Can you provide the expected EPS growth for MEDS stock?
The Earnings per Share (EPS) of TRXADE HEALTH INC (MEDS) is expected to grow by 57.14% in the next year.